Shares Of A Biotech Company That DIDN'T Make The Drug That Saved The Ebola-Infected Doctor Are Surging
Dr. Kent Brantly, who had contracted the Ebola virus in Liberia, was released from Atlanta's Emory University Hospital after being treated with experimental drug ZMapp.
ZMapp was developed by Mapp Biopharmaceutical, a privately held company.
It's not to be confused with MAP Pharmceuticals, which was acquired by Allergan in 2013.
Tekmira Pharmaceuticals, which also has an experimental Ebola drug in the works, is up by around 5% in pre-market trading. It's unclear why.
Here's the after-hours and pre-market moves in Tekmira according to MarketWatch.
- Chris Christie Got Into A Heated Argument About Bruce Springsteen
- Investor Allegedly Emails Female Startup Employee: 'I'm Not Leaving Without Having Sex With You'
- Biotech Stock Achillion Is Soaring After Good News About Its Hepatitis C Drug